Clinical Scorecard: Managing Chronic Lymphocytic Leukemia in India: Navigating Evidence, Accessibility, and Cost in Clinical Settings

At a Glance

Key Highlights

• CLL accounts for ~5% of leukemias in India, with increasing diagnoses due to better awareness.
• Indian patients present at a younger age and often at more advanced stages compared to Western cohorts.
• Molecular profiling for risk stratification is evolving but remains limited in access across India.
• Bruton tyrosine kinase inhibitors (BTKi) and BCL-2 inhibitors show superior efficacy over traditional therapies.
• Access to targeted therapies is influenced by economic constraints and healthcare infrastructure.

Guideline-Based Recommendations

Diagnosis

• Diagnosis established by peripheral blood flow cytometry with characteristic immunophenotype.

Management

• Adoption of targeted agents like BTKi and BCL-2 inhibitors, balancing biological risk with access.

Monitoring & Follow-up

• Monitoring for minimal residual disease (MRD) and long-term toxicity surveillance is essential.

Risks

• Limited access to molecular diagnostics may impact therapeutic decision-making.

Patient & Prescribing Data

Patients with CLL in India, particularly those with TP53 mutations.

Generic ibrutinib has improved access, but uptake of venetoclax-based regimens is limited by cost.

Clinical Best Practices

• Improve access to molecular diagnostics and targeted agents.
• Consider health-policy reforms to enhance treatment affordability and availability.

Related Resources & Content

• Source Article